Market Overview

SunTrust Highlights Upcoming Pharma Calendar, Favorite Names

Share:
SunTrust Highlights Upcoming Pharma Calendar, Favorite Names

As the new week starts, SunTrust gave multiple reasons why they believe the pharmaceuticals group can outperform in 2016. SunTrust believes upward pressure on pharma names can be attributed to innovative new product cycles, accelerating long-term growth rates, an attractive 3 percent dividend yield and a favorable rising interest rate environment.

To take advantage of pricing concerns, SunTrust reviewed what may be key meetings and conferences this week in the pharmaceuticals sector.

  • European League Against Rheumatism: June 8-11
  • European Hematology Association: June 9-12
  • American Headache Society: June 9-12
  • American Diabetes Association: June 10-14
  • Associated Professional Sleep Societies: June 11-15

As for their favorite names in the space, based on growth and value, SunTrust said Bristol-Myers Squibb Co (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY) and AbbVie Inc (NYSE: ABBV). However, Shire PLC (NASDAQ: SHPG) is actually their top name, and Supernus Pharmaceuticals Inc (NASDAQ: SUPN) rounds out their bullish picks as a specialty pharma "catch-up" trade.

The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) was trading down 0.91 percent at $265.17.

 

Related Articles (IBB + LLY)

View Comments and Join the Discussion!

Posted-In: SunTrustAnalyst Color Biotech Previews Events Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
GSCitigroupMaintains370.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com